PTAB Grants Discovery to Underlying Test Data

by BakerHostetler


Discovery in inter partes review (IPR) proceedings at the Patent Trial and Appeal Board (PTAB) is typically quite limited, and the PTAB normally is reluctant to grant motions for additional discovery. It is instructive, therefore, when the PTAB does so. In a recent order in Mylan Pharmaceuticals Inc. v. Allegan, Inc., IPR2016-01127, Paper 28 (PTAB May 31, 2017) (Order), the PTAB granted a motion in part for additional discovery for pharmacokinetic (PK) data underlying figures in certain exhibits that had been submitted in Rule 132 declarations during the prosecution of one of the patents-at-issue, U.S. Patent No. 8,685,930. In particular, declarations of Drs. Schiffman and Attar were said to include figures used to allege the criticality of, and unexpected results from, a claimed formulation to treat dry eye, also known as keratoconjunctivitis sicca (Paper 27 at 2). After going through the Garmin factors, the PTAB ultimately allowed the additional discovery in part (Order at 3-5).[1]

The PTAB found the first Garmin factor to be the most relevant, i.e., whether or not there is more than a possibility and mere allegation that something useful will be discovered (Order at 3). The PTAB focused on the fact that figures relied on in the declarations “failed to provide the necessary parameters for scientific interpretation, including raw data values and error rates” (id.). The PTAB agreed with Petitioner that such “underlying data is necessary to evaluate figures fully, will aid Petitioner’s rebuttal to Patent Owner’s arguments and evidence, and will afford Petitioner a fair cross-examination of Patent Owner’s witnesses” (id.). Based on the same motion, the PTAB denied discovery into data underlying figures from a separate, peer-reviewed publication that summarized the efficacy data of Patent Owner’s phase 2 and phase 3 clinical trial studies (id. at 4). These figures were distinguished in that, unlike in the Schiffman and Attar declarations, the figures included mean value and error rates (id.).

In support of its motion, Petitioner pointed to an IPR (Corning)[2] in which the PTAB ordered production of underlying data necessary to evaluate an expert’s conclusions (Paper 23 at 5). Interestingly, the Patent Owner tried to distinguish Corning by arguing that the underlying data was generated specifically for the IPR; in contrast, the data underlying the declarations in this case was not generated for the IPR (Paper 27 at 6-7). Although the PTAB “note[d] that . . . [37 C.F.R.] § 42.65 favors the disclosure of the underlying facts or data on which an expert’s testimony is based” (Order at 3), which may be a tangential reference to the Corning argument, the PTAB did not otherwise address the Patent Owner’s attempt to distinguish data created for an IPR from data that is not.

Notably, while 37 C.F.R. § 42.65(b)[3] requires data to be submitted in a declaration that meets specific requirements, there is no indication in the Order or the accompanying party briefs that Patent Owner submitted a declaration meeting these requirements, or that the Petitioner objected to the lack of such a declaration. Although not an issue in this case, another provision relevant to data submissions in IPR proceedings is 37 C.F.R. § 42.61, which is directed to admissibility of a “specification or drawing” of a United States patent application or patent. In particular, § 42.61(c) states that “[i]f there is data in the specification or a drawing upon which a party intends to rely to prove the truth of the data, an affidavit by an individual having first-hand knowledge of how the data was generated must be filed.” Thus, if a party intends to rely on the data in the challenged patent itself, an affidavit may be required for admissibility purposes.

Accordingly, parties should carefully consider any data being presented, regardless of when or where generated, to determine if grounds for objection or additional discovery are warranted. Likewise, parties seeking to rely on such data should be prepared to submit the affidavits required under §§ 42.61 and 42.65.[4]

[1] The PTAB has identified the following five factors in determining whether additional discovery is in the interests of justice: (1) more than a possibility and mere allegation that something useful will be discovered; (2) requests that do not seek the other party’s litigation positions and the underlying basis for those positions; (3) ability to generate equivalent information by other means; (4) easily understandable instructions; and (5) requests that are not overly burdensome to answer. Garmin Int’l, Inc. v. Cuozzo Speed Techs. LLC, IPR2012-00001, slip op. at 6-7 (PTAB Mar. 5, 2013) (Paper 26) (informative).

[2] Corning Inc. v. DSM IP Assets B.V., IPR2013-00043, Paper 27 (PTAB June 21, 2013).

[3] The text of 37 C.F.R. § 42.65 is as follows: Expert testimony; tests and data. (a) Expert testimony that does not disclose the underlying facts or data on which the opinion is based is entitled to little or no weight. Testimony on United States patent law or patent examination practice will not be admitted. (b) If a party relies on a technical test or data from such a test, the party must provide an affidavit explaining: (1) Why the test or data is being used; (2) How the test was performed and the data was generated; (3) How the data is used to determine a value; (4) How the test is regarded in the relevant art; and (5) Any other information necessary for the Board to evaluate the test and data.

[4] On June 12, 2017, the PTAB issued an order effectively mooting a large portion of the order discussed in this post that allowed additional discovery into the data underlying the Schiffman and Attar declarations (Paper 33). Specifically, in a dispute regarding the scope of the additional discovery order, the parties agreed that the data underlying several of the exhibits in these declarations pertained to clinical data, not PK data (id. at 2). In addition, Patent Owner represented that those exhibits are not necessary to support its case (id.). Given these facts, the PTAB acknowledged that its original order pertained only to PK data, not clinical data, and since the parties agreed the data underlying certain exhibits in the declarations related only to clinical data, such data was outside the scope of the additional discovery order. Accordingly, the additional discovery order now pertains only to Exhibit C in the Schiffman declaration and Exhibit B in the Attar declaration. The PTAB additionally warned that if the excluded exhibits are used in the proceeding, they will be given no weight per § 42.65, since the underlying data is not being produced.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© BakerHostetler | Attorney Advertising

Written by:


BakerHostetler on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.